WAXMAN COUNTERS CRITICS OF BIOLOGICS BILLS

MAY 01, 2007

House Oversight Committee Chairman Henry Waxman (D, Calif) fired back at brand name drug industry critics of proposals to streamline approvals of generic biologics, charging that critics of the pending legislation are attempting to cloud the debate with misinformation. During a new round of congressional hearings on the proposed bills, Waxman argued that "the big brand name companies have gone beyond legitimate concern and have thrown up a defensive smoke screen around biologicals. They say there will be problems of safety, decreased innovation, and limited savings,"he said.

"A new path for FDA to approve generic biologicals will save patients billions in the future and will improve access to treatments and cures,"Waxman said. "For the sake of patients, their families, public and private health insurance, and taxpayers, we must find a way to introduce competition to this market. When a patent expires, we owe it to consumers to find a way, through competition, to lower prices and still deliver a safe and effective product," he added.




SHARE THIS SHARE THIS
0

Become A RESPIMAT T.O.P. Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?


Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.